DEX‐Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T‐Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy (Adv. Sci. 19/2023)

T‐Cell Acute Lym‐phoblastic Leukemia In article number 2205854, Jingjing Ye, Min Ji, Chunyan Ji, and co‐workers observed aberrant adipogenesis in the bone marrow of chemotherapy‐treated T‐cell acute lymphoblastic leukemia (T‐ALL) patients, and the differentiated‐adipocytes attract and support residu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Ruinan, Sun, Tao, Zhao, Xin, Li, Guosheng, Xia, Yuan, Zhou, Ying, Li, Wěi, Li, Wei, Ma, Daoxin, Ye, Jingjing, Ji, Min, Ji, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Back Cover
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323612/
http://dx.doi.org/10.1002/advs.202370125
Descripción
Sumario:T‐Cell Acute Lym‐phoblastic Leukemia In article number 2205854, Jingjing Ye, Min Ji, Chunyan Ji, and co‐workers observed aberrant adipogenesis in the bone marrow of chemotherapy‐treated T‐cell acute lymphoblastic leukemia (T‐ALL) patients, and the differentiated‐adipocytes attract and support residual T‐ALL cells. Last, an SREBF1 inhibitor demonstrates superior improvement on therapeutic effect of dexamethason by reducing adipogenesis and provides a feasible strategy to solve the dilemma of recurrence. [Image: see text]

Ejemplares similares